Raymond James Financial
PRQR icon

Raymond James Financial’s ProQR Therapeutics PRQR Stock Holding History

Raymond James Financial’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$885K Buy
546,079
+203,193
+59% +$333K ﹤0.01% 3947
2025
Q4 		$693K Buy
342,886
+232,616
+211% +$544K ﹤0.01% 4032
2025
Q3 		$235K Buy
110,270
+14,549
+15% +$31.8K ﹤0.01% 4535
2025
Q2 		$195K Sell
95,721
-6,395
-6% -$10.4K ﹤0.01% 4529
2025
Q1 		$136K Buy
102,116
+4,188
+4% +$8.91K ﹤0.01% 4495
2024
Q4 		$260K Buy
+97,928
New +$311K ﹤0.01% 4265

Other funds holding PRQR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Raymond James Financial's PRQR Position: Q1 2026 in Review

Raymond James Financial increased its ProQR Therapeutics (PRQR) stake by 59% in Q1 2026, buying an estimated $333K and bringing the position to 546,079 shares worth $885K. The position accounts for ﹤0.01% of the portfolio, ranked #3947.

Raymond James Financial first reported a position in PRQR in Q4 2024 and has held it in 6 quarters since. 69 funds tracked by Wall St. Rank hold PRQR as of Q1 2026.

  • Raymond James Financial held 546,079 shares of ProQR Therapeutics worth $885K as of Q1 2026.
  • Raymond James Financial bought 203,193 ProQR Therapeutics shares in Q1 2026, an estimated $333K.
  • ProQR Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #3947 holding.
  • Raymond James Financial first reported a position in ProQR Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 69 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.